News about 'Announcements'

The 21st Stop TB Partnership Coordinating Board retreat and meeting officially started in Bangkok, Thailand, on Sunday, Janu a ry 29th with the official opening ceremony held yesterday January 30th. Below are some exciting news from the meeting courtesy of Mark Harrington, Executive Director of the...

On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC , CPTR , INTERTB , NIH , and TB Alliance . The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in...

Click here for full report. Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been...

Click here for full report Source: Stop TB Partnership News, November 3, 2011 A plan targeting researchers around the world and providing them with a framework to achieve the research objectives of the the Global Plan to Stop TB 2011-2015 and beyond, towards elimination of TB, was launched on...

2011 WGND Annual Meeting (Lille, France) During last week, the Stop TB Partnership Working Group on New Drugs had a successful annual meeting in Lille, France, in conjunction with the 42nd Union World Conference . There were several updates to the Global TB Drugs Pipeline showing progress toward...

Source: WHO New Release/31 October 11, 2011 WASHINGTON DC, 11 October 2011 – The World Health Organization (WHO) reports for the first time that the number of people falling ill with tuberculosis (TB) each year is declining. New data, published today in the WHO 2011 Global Tuberculosis Control...

Yesterday, BBC News published an article on the WHO Plan entitled “Consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO European Region 2011–2015.” The plan outlines the problem as well as a solution that could save 120,000 lives if...

We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2011 at the Grand Palais in Lille, France, on October 26. Also, we are sponsoring a dinner on October 25 at Le Barbue d’Anvers in Lille to allow our Sub-groups (Biology/Targets, Candidates, Critical...

Over the last week, some announcements have been released concerning new tools, publications and meeting materials that may be of value to the TB community including materials from the WGND sponsored “Essentiality of Pyrazinamide” Workshop, an interactive map of clinical trials from PACTR , and a...

The Stop TB Partnership has provided information and references to help partners to prepare a successful proposal to The Global Fund to Fight HIV/AIDS, Tuberculosis, and Malaria . The call for Round 11 applications was released on August 15. Go to http://www.stoptb.org/global/tbfriends/ to get more...

Click here for full report A report entitled “An Evaluation of Drug-resistant TB Treatment Scale-up” was issued by the Médecins Sans Frontières (MSF), Partners in Health (PIH), and Treatment Action Group (TAG) on 7 July, 2011 and looks at the factors contributing to the slow progress of efforts to...

These are the facts (source: Time to Act-Save a million lives by 2015 brochure ) : At least one out of three people in the world has latent TB infection, which increases the risk of becoming ill with TB. People living with HIV have an estimated 20 to 30 times greater risk of developing active TB...

MIchael D. Iseman Dr. Michael D. Iseman, a world renowned pulmonologist and leading expert on tuberculosis has joined Oxford Immunotec as the Senior Scientific Advisor. To read full story, click here . In May 2010, the WGND had the honor of interviewing Dr. Iseman in our “Voices from the Fight to...

Please take a minute and help us choose a new logo for the Stop TB Partnership’s Working Group on New Drugs (WGND). Since our inception in 2001, the WGND has evolved and expanded greatly. Through our membership and activities, we have been able to contribute to the critical collaborations and...

The MTBVAC01 vaccine candidate, developed to protect people against tuberculosis, will start Phase I clinical trials early in 2012. This was announced by the Spanish biopharmaceutical company Biofabri . The candidate was developed by the University of Zaragoza , Spain and is part of the...